An International Phase 3, Randomized, Double-Blind, Placebo- and Active (Tolterodine)-Controlled Multicenter Study to Evaluate the Safety and Efficacy of Vibegron in Patients With Symptoms of Overactive Bladder
An International Phase 3, Randomized, Double-Blind, Placebo- and Active (Tolterodine)-Controlled Multicenter Study to Evaluate the Safety and Efficacy of Vibegron in Patients With Symptoms of Overactive Bladder
This study is designed to evaluate the safety, tolerability, and efficacy of vibegron administered once daily in patients with OAB.
Inclusion Criteria:
Exclusion Criteria:
Urology Medical History
Albuquerque, New Mexico 87109, United States
Wadsworth, Ohio 44281, United States
Pittsburgh, Pennsylvania 15243, United States
Wroclaw, Woj. Dolnoslaskie 54-144, Poland